Edgar Filing: Jazz Pharmaceuticals plc - Form 4

| Jazz Pharmac | ceuticals plc | | | | | | | | | | |
|--|---|------------------|--|--------------|--|--|---|--|-----------------|------------------------|--|
| Form 4 | | | | | | | | | | | |
| August 11, 20 | 015 | | | | | | | | | | |
| FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION | | | | | | | | | PPROVAL | | |
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | OMB Number: | 3235-0287 | | |
| Check this box | | | | 0 / | | | | | Expires: | January 31 | |
| if no long subject to Section 10 Form 4 or | F CHANGES IN BENEFICIAL OWNERSHIP SECURITIES | | | | | NERSHIP OF | Expires. 200: Estimated average burden hours per response 0. | | | | |
| Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940 | | | | | | | | | | | |
| (Print or Type R | lesponses) | | | | | | | | | | |
| 1. Name and Address of Reporting Person <u>*</u> Mulligan Seamus | | | 2. Issuer Name and Ticker or Trading Symbol | | | | - | 5. Relationship of Reporting Person(s) to Issuer | | | |
| | | | Jazz Pha | rmaceutio | cals plc [| JAZ | ZJ | (Check all applicable) | | | |
| (Last) (First) (Middle) | | | 3. Date of Earliest Transaction | | | | | | | | |
| PLC, CONN | HARMACEU AUGHT HOU ON RD., FL. 4 | USE, 1 | (Month/Da 08/07/20 | - | | | | X Director Officer (give below) | | 6 Owner er (specify | |
| | (Street) | | 4 If Δmer | ndment, Dat | te Original | | | 6 Individual or I | oint/Group Fili | ng(Check | |
| · · · · | | | | th/Day/Year) | - | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| (City) | (State) | (Zip) | | | • .• . | | | | a D at . | | |
| | () | (| Table | e I - Non-D | | | ties Ac | quired, Disposed o | | - | |
| 1.Title of Security (Instr. 3) | 2. Transaction I (Month/Day/Ye | ar) Executionany | med 3. 4. Securities on Date, if TransactionAcquired (A) or Code Disposed of (D) Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| Ordinary Shares | 08/07/2015 | | | A <u>(1)</u> | 1,310 (1) | A | \$ 0 | 1,158,515 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Jazz Pharmaceuticals plc - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. 5. Number Transaction of Derivative Code Securities (Instr. 8) Acquired (A) or | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | |
|---|---|---|---|---|---|--|---------------------|--|--------------------|--|
| | Security | | | | (A) of Disposed of (D) (Instr. 3, 4, and 5) | | | | | |
| | | | | Code V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Nonstatutory Stock Option (right to buy) | \$ 181.79 | 08/07/2015 | | А | 3,415 | | (2) | 08/06/2025 | Ordinary Shares | 3,415 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | |
|---|---------------|------------|---------|-------|--|--|
| | Director | 10% Owner | Officer | Other | | |
| Mulligan Seamus C/O JAZZ PHARMACEUTICALS PLC CONNAUGHT HOUSE, 1 BURLINGTON RD., FL. 4 DUBLIN, L2 4 | Х | | | | | |
| Signatures | | | | | | |
| /s/ Larissa Schwartz as attorney in fact for Seamus | | 08/11/2015 | | | | |

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These restricted stock units are granted pursuant to the Issuer's 2007 Equity Incentive Plan. Each restricted stock unit represents a (1) contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and

- certain additional conditions, these units will vest in full on July 30, 2016.
- (2) This option is granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vests in 12 equal monthly installments beginning on August 1, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

.....

Date